Genera Research Ltd.
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Regenerative Medicine
Genera Research Ltd. is a clinical-stage biotechnology company based in Croatia, and the country's first biotech, pioneering regenerative medicine through recombinant human Bone Morphogenetic Protein 6 (rhBMP-6). Its flagship product, OSTEOGROW-C, is entering Phase III clinical trials for bone fracture nonunion and dental indications, with more than 300 patients treated to date demonstrating strong safety and efficacy. OSTEOGROW's core innovation is the use of autologous blood coagulum as a natural carrier for rhBMP-6: when implanted directly into the fracture site, it enables complete bone regeneration with no adverse events reported. This proprietary delivery technology is protected by patents valid until 2043. Through strategic collaborations with academic institutions, hospitals, and industry partners across Europe, Genera Research is committed to delivering innovative, safe, and effective regenerative therapies for unmet medical needs in bone and tissue repair worldwide.
Company HQ City:
10436 Sveta Nedelja, Croatia
Company HQ State:
Croatia
Company HQ Country:
Croatia
Year Founded:
2021
Lead Product in Development:
OSTEOGROW-C
CEO
Prof. Slobodan Vukičević, PhD, MD
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
3 (non-unions, dental, spinal application)
When you expect your next catalyst update?
March 2027 — Phase III protocol regulatory approval
What is your next catalyst (value inflection) update?
Genera Research is approaching its most significant value inflection point to date: the initiation of Phase III clinical trials for OSTEOGROW, our proprietary rhBMP-6 therapy delivered via autologous blood coagulum, in bone fracture nonunion and dental indications. This milestone is built on a robust foundation of Phase I/II clinical data from more than 300 patients, demonstrating complete bone regeneration with no serious adverse events — outcomes unmatched by any competing BMP-based product. The Phase III program will generate the pivotal evidence required for EMA and FDA marketing authorization, opening access to multi-billion-dollar global markets in orthopedic and dental regenerative medicine. In parallel, we anticipate additional value-creating milestones including expansion of our patent portfolio (currently protected until 2043), strategic licensing and partnership agreements, and the initiation of clinical programs in adjacent indications such as spinal fusion. For investors entering now, this represents a rare opportunity to participate ahead of multiple near-term catalysts that will drive substantial valuation uplift.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}